No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
ENOV240517C50000
- 1.55
- -0.45-22.50%
15min DelayClose May 10 16:00 ET
1.55High1.55Low
1.55Open2.00Pre Close10 Volume0 Open Interest50.00Strike Price1.55KTurnover18.99%IV0.35%PremiumMay 17, 2024Expiry Date1.07Intrinsic Value100Multiplier6DDays to Expiry0.48Time Value100Contract SizeAmericanOptions Type0.8128Delta0.2086Gamma40.86Leverage Ratio-0.0330Theta0.0071Rho33.21Eff Leverage0.0182Vega
Intraday
- 5D
- 1D
News
Top 4 Health Care Stocks Which Could Rescue Your Portfolio This Month
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.The RSI is a momentum indicator, which compares a stock's strength on days when prices go u
Enovis (NYSE:ENOV Shareholders Incur Further Losses as Stock Declines 8.3% This Week, Taking Three-year Losses to 30%
For many investors, the main point of stock picking is to generate higher returns than the overall market. But its virtually certain that sometimes you will buy stocks that fall short of the market a
Enovis Corporation (NYSE:ENOV) Q1 2024 Earnings Call Transcript
A Closer Look at 6 Analyst Recommendations For Enovis
In the latest quarter, 6 analysts provided ratings for Enovis (NYSE:ENOV), showcasing a mix of bullish and bearish perspectives.In the table below, you'll find a summary of their recent ratings, revea
Express News | Needham Reiterates Buy on Enovis, Maintains $82 Price Target
Enovis Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/03/2024 48.77% Needham → $82 Reiterates Buy → Buy 04/10/2024 48.77% Needham → $82 Reiterates Buy → Buy
Comments
The company's use of debt is seen as risky due to its EBIT loss and the liabilities it has. The balance sheet is not considered strong, but it could improve over time. The stock is considered quite risky.
Here's Why Enovis (NYSE:ENOV) Can Afford Some Debt 1
Needham analysts predict Enovis's new products, orthopedic market strength, and the Lima acquisition will exceed 2024 consensus. They also foresee Paragon 28 returning to roughly 20% revenue growth in 2024 due to new bunion-focused products, supply chain enhancements, and sales force growth.
Enovis CEO Matt Trerotola praised Shirley, Vogt, and Ross for their roles in the company's growth. He highlighted Shirley's influence on Enovis's transformation to a medtech firm, Vogt's contribution to the U.S. surgical business growth, and Ross's work in ensuring sustained growth in the P&R segment.
Enovis' falling revenue and absent profits might have led to a drop in share price. Viewing the total shareholder return and recent share price rise, the company may suggest investment potential if it shows sustainable long term growth.
Enovis's rise in liabilities and recent EBIT loss spark concerns about its debt use and future profitability. With a negative free cash flow of US$106m over the past year, the company's financial risk is evident. Balance sheet situation calls for caution due to dubious circumstances.
Read more